EZH2 and central nervous system cancer: Although loss- and gain-of-function EZH2 mutations have been documented in lymphomas, myeloid malignancies, leukemias, and solid tumors, only truncating mutations in the H3K36 methyltransferase SETD2 [17] have been reported in pediatric high-grade gliomas (pHGG).